San Diego-based HemaQuest Pharmaceuticals said today that it has raised $13M in a Series B funding. The firm, which is developing small molecule therapeutics for treating hemoglobin disorders such as sickle cell disease, said the funds come in the form of a Series B extension, coming from existing investors Aberdare Ventures, De Novo Ventures, Forward Ventures, Latterell Venture Partners and Lilly Ventures. The new funds will go towards a Phase 2b clinical study to apply its compound to patients with sickle cell disease. More information »